Sildenafil Tablet, Film Coated
Product Images NDC 43063-982

This is a medication information sheet for Sildenafil, a drug that comes in 20mg tablets and is used to treat certain types of erectile dysfunction in men. The text includes details about the product, such as the lot number, expiration date, and dosage instructions. It also gives a warning about potential side effects and provides an FDA contact number for reporting them. The text also contains some technical information for pharmacists, including the NDC number and the drug's chemical makeup.*

This appears to be a chart showing the estimated cumulative mortality rate given different doses of some substance over time in years. The rates are given in percentages and high, medium, and low doses are compared.*

This text appears to be a chart or table that provides recommendations for dose adjustments of different drugs when administered with Sildenafil. The chart includes drug names, specific measurements such as AUC (area under the curve) and Cmax (maximum plasma concentration), and whether a dose adjustment is recommended or not for each drug when taken with Sildenafil. Additionally, it includes some notes about the clinical studies, the lack of benefit on exercise capacity when sildenafil added to bosentan therapy, and a line graph depicting the change relative to Sildenafil alone.*

This is a list of interacting drugs with Acenocoumarol. The data presented includes the effects on different parameters, such as INR, AUC, Cmax and BT, as well as recommendations on dose adjustments. No adjustments are needed for most drugs, but coadministration with some drugs is not recommended. The effect of ritonavir on sildenafil PK is also described.*

This is a graphical representation of the change from baseline in 6-minute walk distance in a study that evaluated a placebo and two doses of sildenafil (40mg and 80mg) at weeks 4, 8, and 12. The mean and 95% confidence intervals are shown in meters. No useful information can be extracted from the output provided.*

This is a statistical graph showing the placebo-corrected change from baseline in 6-minute walk distance (meters) at week 12 by study subpopulation in Study 1. The graph displays mean values with a 95% confidence interval. There are several categories of the subpopulation, including idiopathicPAH, etiology PHCD, PAH-surgical repair, PH etiology for functional capacity, and therapeutic class. There are also details given for baseline walk and distance (in meters), the number of people in each subpopulation group, median age, mean PAP, and PR. The x-axis is the Placebo-corrected Change in 6-Minute Walk Distance (m), while the y-axis is the study subpopulation.*

The text describes a Kaplan-Meier plot that displays the time (in days) to clinical worsening of PAH in Study 2. The x-axis represents the days from randomization, and the y-axis represents the percentage without a clinically worsening event. The plot compares two interventions, Placebo, and Sildenafil. The description does not provide any further information or context regarding Study 2 or the interventions used.*

The text contains data related to a study analyzing the mean change from baseline for different treatments over a period of 12 weeks. The treatments mentioned are Sidenafil in different doses (5mgTD, 20mg TID). However, the text is not complete and does not provide sufficient information to understand the study in detail.*